Ultimovacs is a pharmaceutical company developing novel immunotherapy against cancer. Our leading product is UV1, a therapeutic cancer vaccine (TCV) directed against human telomerase (hTERT). The vaccine is a result of many years of pre-clinical and clinical research at the Norwegian Radium Hospital. UV1 is a synthetic peptide vaccine.
The peptides included in the vaccine are based on observation of immune responses in patients with advanced malignant disease surviving several years after vaccination with a hTERT based therapeutic cancer vaccine.
The company is currently performing three clinical trials with UV1.
Two trials are documenting safety and the vaccines ability to activate the immune system against cancer cells expressing the hTERT fragments that are the components of the vaccine when given as a single treatment.
A third clinical trial is assessing safety and clinical outcomes when combining UV1 with ipilimumab in patients with malignant melanoma.
The major owners of Ultimovacs are Gjelsten Holding AS, The Norwegian Radium Hospital Research Foundation, Inven2 AS, Canica AS, Sundt AS, Watrium AS, Langøya Invest AS and Prius AS. Ultimovacs is located at Oslo Cancer Cluster Innovation Park and is an active member of Oslo Cancer Cluster.